On April 2, 2018, Shenrui Medical officially announced the completion of the B round of financing of 150 million yuan, led by Junlian Capital, Lenovo Star and investment, A round and A + round investment side Danhua Capital, Kunzhong Capital, Daoyi Investment, With the capital, Hongdao Capital continued to follow suit. So far, in the year of establishment, the cumulative financing amount of A round, A+ round and B round has reached 300 million yuan, which is rare in the industry.
The 2018 work report of the two sessions mentioned the keyword of artificial intelligence many times. This year's government work report emphasizes “strengthening the application and development of a new generation of artificial intelligenceâ€. In the ever-increasing wave of artificial intelligence, application landing has become the trend of the times. As a leader in the artificial intelligence + medical industry, Shen Rui not only promotes the technological innovation of artificial intelligence medical treatment, but also strives to promote the application of artificial intelligence.
Just one year after the establishment of Shenrui Medical, it has been closely following the policy and has been deeply involved in the field of artificial intelligence + medical. The company has led the breakthrough of artificial intelligence "deep learning" technology and built the world's top core algorithm technology. Shen Rui doctor artificial intelligence system, applying the latest technology of AI, the medical image disease diagnosis results have reached the international leading level. The product developed by the company and a number of scientific research institutions has been put into use by more than 100 hospitals. At the same time, with the strong support of Zhejiang University and its affiliated hospitals, Shenrui Intelligent will set up the Shenzhen Rui Aixiang headquarters artificial intelligence precision diagnosis and treatment center in April. In 2018, Shenrui Medical accelerated its development and actively cooperated with top hospitals at home and abroad to continuously expand the ecological circle and deepen the vertical product field, especially the solutions for common diseases with a wide range of foundations. In the era of artificial intelligence, in the entire medical intelligence or medical technology industry, the replacement of technology will have a very big impact on the industry, and more importantly, the clinical needs of hospitals and doctors working in the front line. And this is the corporate mission of Shenrui Medical.
Shen Rui Medical CEO Qiao Wei has always believed that Shen Rui Medical is a clinical application-driven company that has been conducting research around the needs of clinicians. Chaucer is convinced that meeting the clinical needs is the real value of the company. At the beginning of the founding team, the company proposed the development vision of “making the doctor no longer difficultâ€, planning the development blueprint for the next five years, and creating a forward-looking AI medical closed loop. The ecological circle includes general consultation, early investigation, accurate diagnosis, medical record data mining, and surgical intelligent navigation. Covering the entire medical process of triage, examination, diagnosis, treatment and follow-up, such products can make artificial intelligence be really needed by the medical industry! At present, the application of artificial intelligence in the medical field is still in a relatively shallow stage, and Shenrui Medical believes The application of artificial intelligence in the medical field has great potential. In the future, artificial intelligence will have more perfect performance in various fields of medical treatment, and at the same time, it will effectively integrate and enhance the existing level of diagnosis and treatment. Shenrui will invest more in this field in the future. More resources. In the next step, Shenrui will do its utmost to implant artificial intelligence into various medical scenarios to achieve real-world technology.
Mr. Li Jiaqing, the managing director of Junlian Capital, who led the round, pointed out: "Medical imaging is the most important clinical diagnosis and differential diagnosis tool in modern medicine. The continuous enrichment of imaging technology has transformed medical imaging from auxiliary inspection tools to current doctors for diagnosis. The largest information portal, nearly 70% of clinical diagnosis requires medical imaging. The value of medical imaging AI is to achieve efficient cooperation between clinicians and imaging doctors, reduce the rate of misdiagnosis, when data becomes a new production factor, artificial intelligence technology creates A new supply of medical services. However, artificial intelligence only has a single breakthrough in medical imaging. It is not enough to understand the medical industry's application to the product. Shenrui is a company in the field of AI imaging, scientific research level, engineering technology. , product design, marketing and other comprehensive capabilities in the industry-leading medical AI technology companies, the most opportunity to stand out in the market competition."
It is reported that Junlian's layout in the medical AI field, in addition to deep core, also invested in medical pathology company Di Yingjia, South Korea X-ray imaging company Lunit, gene big data company Jianlu gene, etc., plus the earlier in the field of medical testing Investing in third-party medical testing leader Jinyu Medical, gene sequencing company Berry and Kanghe digital imaging equipment provider Kangzhong Medical, Kangda Medical, in the future, with the industrial resources of Junlian Capital, Shenrui will explore and related corporate exhibitions The application cooperation creates synergies.
Mr. Zhang Dadi, founding partner of A+ Wheels, the Danhua Capital China Fund, said that Shenrui is a company that is rare in the AI ​​medical field and has a first-class artificial intelligence technology reserve and a deep accumulation and insight into the medical industry. An important factor in the success of a startup is its comprehensive ability. In particular, the threshold of the industry like medical care is very high, and the management of the startup team must have a foundation and influence in the industry. Shen Rui CEO Qiao Wei worked in the Siemens Medical Imaging Division for nearly 15 years and served as the general manager. He is a well-known veteran in the industry, has deep and clear understanding and insight into the medical imaging industry, and has managed a large team of hundreds of people. . Most of the core technical staff are from the BAT senior development team, many of whom have PhDs and strong R&D capabilities. Mr. Zhang Dadi is very optimistic about the Shen Rui team with Chaucer as the core. Such an elite team is fully committed to the domestic AI medical industry, which is full of opportunities. It has the conditions and strength of the industry leader and will definitely create a pattern and achievements. A unicorn business in the AI ​​medical field.
A round of lead investment, the current round of continued investment with Kunzhong Capital founding management partner Wang Wei believes that Shen Rui's product line has made great progress in the past year. At the same time, the team of Shenrui has also been greatly enhanced, gathering a group of talents in the field of artificial intelligence, medical imaging, big data and other fields at home and abroad. Kunzhong has made extensive and in-depth layouts in the field of artificial intelligence. We believe this is a long track, and Shenrui has the potential to be a frontrunner.
Sun Qi, an investment management partner of Dow Investment, said that Dow Investment is an early investor in Shenrui Medical. This financing continues to be pursued, indicating that Dow Investment is optimistic about the development of artificial intelligence and its changes from the supply side to the medical industry. Rui Medical has the potential to become a leader in the industry. The Shenrui team also has a rich background in the medical industry and artificial intelligence technology background. The rich pipeline can be well integrated with the medical scene. It is based on the deep understanding of medical treatment that Shenrui's products are closer to the needs of clinicians. Really integrate AI diagnostic methods into existing medical treatment processes to improve the efficiency and level of existing medical services. We are very willing to work together with TMT Fund to invest in the rich medical service resources and medical industry layout to help Shenrui develop faster and longer.
Ms. Wu Ronghui, the founding managing partner of Tongdu Capital, believes that Shenrui is the fastest runner in the relatively crowded medical imaging AI track. Although just established in 2017, in just one year, the company's progress in business and financing is amazing, mainly due to the team's two years of accumulation in the technical product end and more than 20 years of experience in the medical imaging industry. It is precisely because of the deep industry accumulation that Shenrui can quickly find suitable clinical application scenarios, allowing products to land faster; it can also grasp the key nodes of medical imaging AI, an innovative product industry application. Tongdu will continue to support teams in the industry and technology complex background of Shenrui to jointly promote artificial intelligence to improve the service quality and cost structure of the medical industry.
After the financing, Shenrui Medical will speed up the research and development of artificial intelligence products for various diseases, and accelerate the clinical inspection speed of artificial intelligence products. In 2018, Shen Rui will be quick-moving, speeding up development, and constantly innovating and benefiting patients, making it no longer difficult to see a doctor.
Esd Tvs Diode,Esd Protection Diode,Esd Suppressor Diode,Usb Esd Protection Diode
Shenzhen Kaixuanye Technology Co., Ltd. , https://www.iconlinekxys.com